Description
Nasal Spray Format
This product is a liquid research preparation at a concentration of 1 mg/mL (10 mg total peptide in 10 mL), supplied with a metered nasal‑spray pump for research applications where intranasal administration is the study route. The intranasal route offers partial access to CNS tissue via the olfactory and trigeminal pathways, bypassing first‑pass hepatic metabolism.
Intranasal pharmacology varies substantially by molecule. Small, lipophilic peptides may achieve meaningful CNS concentrations; larger or highly hydrophilic peptides often do not. Peer‑reviewed data for intranasal PK is referenced below where available.
Parent Compound: MT-2
Melanotan‑2 (MT‑2) is a cyclic heptapeptide non‑selective melanocortin receptor agonist. It is not FDA‑approved. Recreational‑use adverse events reported in the literature include rhabdomyolysis, atypical melanoma presentations, and priapism.
Intranasal Research Context
- Published peer‑reviewed data on intranasal MT‑2 is extremely limited. The original pharmacology studies (Dorr 1996; Wessells 2000) used SC administration.
- Intranasal route is used anecdotally in the vendor/recreational community; systemic bioavailability via this route is not formally characterized.
Preparation Details
- Total peptide: 10 mg MT‑2
- Volume: 10 mL
- Concentration: 1 mg/mL
- Format: Metered nasal‑spray pump
- Source: Solid‑phase synthesis; ≥98% HPLC, reconstituted in preservative‑containing sterile saline buffer
Known Side Effects — MT-2 Class
- Nausea, flushing (very common with systemic absorption)
- Generalized skin darkening; new or darkened nevi — dermatologic surveillance warranted
- Spontaneous erection, yawning, fatigue
- Case reports: rhabdomyolysis, priapism, atypical melanoma in recreational‑use literature
- Not FDA‑approved; safety data sparse
Storage & Handling
- Lyophilized (unreconstituted) vials: store at −20°C long‑term; short‑term 2–8°C acceptable.
- After reconstitution with bacteriostatic or sterile water: store at 2–8°C; use within 14–28 days per standard peptide stability guidance.
- Protect from light, heat, and repeated freeze‑thaw cycles. Handle in a sterile laboratory environment.
Certificate of Analysis
A Certificate of Analysis (COA) confirming identity and purity by HPLC / MS is available upon request. Contact Lonestar Peptides for lot‑specific documentation.
Summaries reference peer‑reviewed preclinical and clinical literature available as of early 2025. Newer findings may not be reflected. Researchers should consult current literature and conduct their own due diligence. Lonestar Peptides makes no claim of therapeutic benefit.
